Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

ER heart test feedback aims to cut readmissions and deaths in Rapid-Breathing patients

NCT ID NCT05699564

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving doctors early results from heart biomarker tests (NT-proBNP and hs-cTnT) along with a structured interpretation note can improve outcomes for patients admitted with rapid breathing (tachypnea). About 574 adults will be randomly assigned to receive this feedback or standard care. The main goal is to see if the feedback extends the time until a patient is readmitted to the hospital or dies from any cause.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
early biomarker testing (NT-proBNP and hs-cTnT) with structured feedback
What this could lead to
If successful, this could show that early biomarker-guided assessments in the ER help reduce hospital readmissions and deaths in patients with rapid breathing.
What could go wrong
This is a single-center pragmatic trial, not a large Phase 3 study. The intervention is informational feedback, not a drug, so the impact may be modest and may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

574 people

The number who actually took part.

Started

Mar 2023

Expected to finish

Dec 2038

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years old * Tachypnea (respiratory rate ≥20/min) * Admission to Departments under the Division of Medicine at Akershus University Hospital, except the Department of Neurology * \<24 h from hospital admittance to inclusion in the study * Signed written informed consent during the initial phase of the hospitalization Exclusion Criteria: * Previously included into the study (in case of patients presenting with a second hospitalization during the study period) * Known or suspected cancer outside of local control, documented in medical records, at the time of patient inclusion or diagnosed in relation to the index hospitalization * Neurological condition with short life expectancy; e.g. ALS, documented in medical records during screening prior to study entry * Other non-cardiac disease with life expectancy below 1 year, documented in medical records during screening prior to study entry * Obvious non-cardiac cause for tachypnea based on medical records and clinical findings during screening prior to study entry; e.g. anaphylaxis in young patient with known allergy, dyspnea after direct chest trauma, or young patient with fever and positive Covid-19 test on admission. * Patient assessed as non-Internal Medicine patient; e.g. surgical patient * Patients unwilling or unable to comply with the protocol, including Glasgow Coma Scale \<13 on the time of study inclusion * Patients that are intubated for invasive ventilatory therapy before or shortly after hospital admission * History of non-compliance to medical management and patients who are considered potentially unreliable, based on documentation in medical records, during screening prior to study entry * History or evidence of alcohol or drug abuse with the last 12 months, based on medical records and clinical findings during screening prior to study entry, that will influence study participation * Any surgical or medical condition, based on medical records and clinical findings during screening prior to study entry, that will impair the ability of the patient to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure Tachypnea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Akershus University Hospital

    Lørenskog, Lørenskog, 1478, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.